Owczarczyk-Saczonek A, Witmanowski H, Placek W. Case reportAcneiform rash during lung cancer therapy with erlotinib (Tarceva®). Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2013;30(3):195-198. doi:10.5114/pdia.2013.35624.
APA
Owczarczyk-Saczonek, A., Witmanowski, H., & Placek, W. (2013). Case reportAcneiform rash during lung cancer therapy with erlotinib (Tarceva®). Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 30(3), 195-198. https://doi.org/10.5114/pdia.2013.35624
Chicago
Owczarczyk-Saczonek, Agnieszka, Henryk Witmanowski, and Waldemar Placek. 2013. "Case reportAcneiform rash during lung cancer therapy with erlotinib (Tarceva®)". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 30 (3): 195-198. doi:10.5114/pdia.2013.35624.
Harvard
Owczarczyk-Saczonek, A., Witmanowski, H., and Placek, W. (2013). Case reportAcneiform rash during lung cancer therapy with erlotinib (Tarceva®). Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 30(3), pp.195-198. https://doi.org/10.5114/pdia.2013.35624
MLA
Owczarczyk-Saczonek, Agnieszka et al. "Case reportAcneiform rash during lung cancer therapy with erlotinib (Tarceva®)." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 30, no. 3, 2013, pp. 195-198. doi:10.5114/pdia.2013.35624.
Vancouver
Owczarczyk-Saczonek A, Witmanowski H, Placek W. Case reportAcneiform rash during lung cancer therapy with erlotinib (Tarceva®). Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2013;30(3):195-198. doi:10.5114/pdia.2013.35624.
Tyrosine kinase inhibitors are currently applied in the treatment of non-small cell lung cancer with overexpressed epidermal growth factor receptor (EGFR). Acneiform rash is the earliest and most characteristic side effect of EGFR inhibition. The incidence may be as high as 50-100% of cases. We report a case of a 47-year-old patient who developed acneiform rash after 1.5 weeks of treatment with erlotinib.
